Ceapro Inc. develops and utilizes core technologies to supply materials and compounds to the life sciences and personal care and cosmetics industries. The Company discovers, develops, and produces natural health products derived from oats and other grains. Its products include natural active ingredients, including beta glucan, avenanthramides, oat powder, oat oil, oat peptides, and lupin peptides.
Quote | Ceapro Inc (OTCMKTS:CRPOF)
Last: | $0.17 |
---|---|
Change Percent: | 0.0% |
Open: | $0.17 |
Close: | $0.17 |
High: | $0.17 |
Low: | $0.17 |
Volume: | 6,000 |
Last Trade Date Time: | 05/31/2024 03:00:00 am |
News | Ceapro Inc (OTCMKTS:CRPOF)
TORONTO and EDMONTON, Alberta, June 03, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) and Ceapro Inc. (TSX-V: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceutical development companies, ...
2024-05-30 08:22:00 ET More on Ceapro Financial information for Ceapro Read the full article on Seeking Alpha For further details see: Ceapro GAAP EPS of -C$0.02, revenue of C$2.8M
Message Board Posts | Ceapro Inc (OTCMKTS:CRPOF)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $CRPOF News Article - Ceapro Inc. Reports Record Financial Results for First Quarter 20 | whytestocks | investorshangout | 05/18/2022 4:20:50 PM |
whytestocks: $CRPOF News Article - Ceapro Inc. to Present at the H.C. Wainwright BioConnect 2021 Vir | whytestocks | investorshangout | 01/08/2021 3:55:49 PM |
CRPOF Daily Chart | Golden Cross | investorshub | 10/16/2019 7:45:41 AM |
$CRPOF Tier_Change: Pink Current to OTCQX International | Golden Cross | investorshub | 10/16/2019 7:44:21 AM |
Too bad there aren't more people here. Great company | ronpopeil | investorshub | 09/29/2016 10:46:22 PM |
News, Short Squeeze, Breakout and More Instantly...
TORONTO and EDMONTON, Alberta, June 03, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) and Ceapro Inc. (TSX-V: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceutical development companies, ...
– Q1 2024 marked by significant advancement of R&D projects focused on avenanthramide Phase 1-2a clinical study and the processing of yeast beta glucan along with the building of pilot scale units for PGX Technology – Q1 2024 sales of $2,800,000 vs $3,500,0...
Faraday Future Intelligent Electric Inc. (FFIE) is expected to report for Q1 2024 D-Market Electronic Services & Trading (HEPS) is expected to report for Q1 2024 Christian Dior SE ADR (CHDRY) is expected to report for Q1 2024 Check-Cap Ltd. (CHEK) is expected to report $-0.17 for ...